VVOS
Vivos Therapeutics, Inc. NASDAQ Listed Dec 11, 2020$0.45
-9.05%
vs $0.50
Mkt Cap $2.7M
52w Low $0.38
0.9% of range
52w High $7.95
50d MA $0.65
200d MA $1.71
P/E (TTM)
—
EV/EBITDA
—
P/B
—
Debt/Equity
-9.1x
ROE
1420.8%
P/FCF
-0.3x
RSI (14)
34.10
ATR (14)
$0.07
Beta
6.90
50d MA
$0.65
200d MA
$1.71
Avg Volume
3.2M
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. Vivos Therapeutics also offers VivoScore Program, a screening and home sleep test in adults and children. The company markets and sells its Vivos System to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Highlands Ranch, Colorado.
9137 Ridgeline Boulevard · Highlands Ranch, CO 80129 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 15, 2026 | AMC | -0.49 | -0.58 | -17.2% | 1.47 | -15.6% | -25.9% | -10.6% | +3.7% | +2.0% | +0.0% | — |
| Nov 19, 2025 | AMC | -0.53 | -0.49 | +7.5% | 2.36 | -4.2% | -10.2% | +3.8% | -2.3% | +2.3% | +1.8% | — |
| Aug 19, 2025 | AMC | -0.27 | -0.55 | -103.7% | 4.27 | -4.0% | -3.3% | +11.4% | -8.7% | +10.2% | +1.3% | — |
| May 15, 2025 | AMC | -0.44 | -0.45 | -2.3% | 3.06 | -5.2% | -17.0% | -9.1% | -6.9% | -3.3% | +0.5% | — |
| Mar 31, 2025 | AMC | -0.43 | -0.28 | +34.9% | 2.85 | -1.1% | -7.7% | -2.3% | +0.0% | -0.8% | -1.2% | — |
| Nov 14, 2024 | AMC | -0.70 | -0.40 | +42.9% | 3.12 | +1.0% | -9.0% | -4.6% | +4.4% | +2.1% | +2.1% | — |
| Aug 14, 2024 | AMC | -1.05 | -0.60 | +42.9% | 2.37 | +4.2% | -5.1% | +3.6% | +11.6% | +17.3% | -6.9% | — |
| May 14, 2024 | AMC | -1.17 | -1.63 | -39.3% | 2.49 | -14.5% | -12.4% | +3.7% | +1.3% | -2.2% | -1.8% | — |
| Mar 28, 2024 | AMC | -1.90 | -3.05 | -60.5% | 4.83 | -22.4% | -30.2% | +0.6% | -11.2% | +4.3% | -4.1% | — |
| Nov 14, 2023 | AMC | -3.12 | -1.75 | +43.9% | 3.73 | +5.9% | +3.2% | +0.8% | +4.1% | +5.9% | +8.6% | — |
| Aug 16, 2023 | AMC | -3.75 | -3.75 | +0.0% | 8.57 | -5.8% | -6.9% | -1.9% | -11.5% | -4.3% | -1.5% | — |
| Jun 8, 2023 | AMC | -4.25 | -5.00 | -17.6% | 11.75 | +0.0% | -10.2% | +4.3% | +14.5% | -5.6% | +15.8% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 22 | Ascendiant Capital | Maintains | Buy → Buy | — | $1.03 | $1.05 | +1.9% | +0.0% | -13.0% | -6.0% | +2.5% | -1.6% |
| Apr 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.09 | $1.10 | +0.9% | -10.6% | +3.7% | +2.0% | +0.0% | -13.0% |
| Dec 3 | Ascendiant Capital | Maintains | Buy → Buy | — | $2.05 | $2.04 | -0.5% | +1.0% | +3.9% | -3.7% | +4.3% | +0.0% |
| Sep 9 | Ascendiant Capital | Maintains | Buy → Buy | — | $3.83 | $3.83 | +0.0% | +1.0% | -1.6% | -4.5% | -4.7% | -2.6% |
| Apr 15 | Ascendiant Capital | Maintains | Buy → Buy | — | $2.25 | $2.32 | +3.1% | -2.7% | -5.0% | +1.0% | +4.8% | +4.5% |
| Nov 20 | Ascendiant Capital | Maintains | Buy → Buy | — | $2.83 | $2.86 | +1.1% | +2.1% | +2.1% | +8.5% | +5.6% | +4.1% |
| Nov 19 | Alliance Global Partners | Maintains | Buy → Buy | — | $2.71 | $2.63 | -3.0% | +4.4% | +2.1% | +2.1% | +8.5% | +5.6% |
| Aug 20 | Ascendiant Capital | Maintains | Buy → Buy | — | $2.60 | $2.60 | +0.0% | +17.3% | -6.9% | -4.9% | +0.4% | +7.4% |
| Jan 17 | Ascendiant Capital | Maintains | Buy → Buy | — | $43.75 | $45.00 | +2.9% | -6.9% | -6.1% | -2.0% | -9.3% | -2.9% |
| Aug 12 | Roth Capital | Maintains | Buy → Buy | — | $70.50 | $70.50 | +0.0% | -2.8% | +19.3% | -11.9% | +16.8% | +1.3% |
| May 17 | Roth Capital | Maintains | Buy → Buy | — | $149.25 | $148.75 | -0.3% | +1.5% | -4.0% | -3.3% | +0.9% | -0.2% |
| Jan 11 | Craig-Hallum | Maintains | Buy → Buy | — | $155.75 | $159.00 | +2.1% | +16.4% | +12.1% | +0.2% | -2.0% | -5.8% |
| Jan 5 | Roth Capital | Maintains | Buy → Buy | — | $150.25 | $152.50 | +1.5% | +2.7% | +1.9% | +1.6% | -2.5% | +16.4% |
No insider trades available.
8-K · 1.01
!! High
Vivos Therapeutics, Inc. -- 8-K 1.01: Material Agreement
Jun 25
8-K · 1.01
!! High
Vivos Therapeutics, Inc. -- 8-K 1.01: Collaboration Agreement
Jun 16
8-K · 8.01
!! High
Vivos Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Jun 16
8-K · 1.01
!! High
Vivos Therapeutics, Inc. -- 8-K 1.01: Material Agreement
Vivos Therapeutics entered into a material agreement with Streeterville Capital, likely involving financing or strategic support, which could provide capital resources for clinical development or operations.
Jun 8
NT 10-Q
!! High
Vivos Therapeutics, Inc. -- Late Quarterly Report -- Distress Signal
May 15
8-K
Vivos Therapeutics, Inc. -- 8-K Filing
Vivos Therapeutics received a Nasdaq compliance notice requiring stockholders' equity restoration by June 1, 2026, or faces potential delisting.
Apr 22
8-K
Unknown — 8-K Filing
Vivos Therapeutics achieved 16% revenue growth in 2025 and integrated The Sleep Center of Nevada, positioning the company for improved margins and cash flow generation going forward.
Apr 15
8-K · 1.01
! Medium
Unknown — 8-K 1.01: Equity Issuance
VVOS issued equity to V-Co Investors 3 LLC, likely diluting existing shareholders' ownership stakes and potentially signaling the company needed external capital for operations or strategic initiatives.
Apr 3
NT 10-K
!!! Very High
Unknown — Late Annual Report — Distress Signal
Vivos Therapeutics' late annual report filing signals potential financial or operational distress, creating uncertainty about the company's viability and making the stock riskier for investors pending disclosure of its condition.
Mar 31
8-K · 5.02
!!! Very High
Vivos Therapeutics, Inc. -- 8-K 5.02: Executive Change
Vivos Therapeutics appoints Gregg C. E. Johnson as independent director, strengthening board oversight and governance structure for investors.
Feb 6
Valuation
Market Cap
$2.7M
Enterprise Value
$3.6M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.14x
P/B
—
P/S
0.24x
P/FCF
-0.29x
EV/EBITDA
—
Shares Out
10.3M
Financials (TTM)
Revenue
$19.6M
Net Income
-$25.1M
EBITDA
-$23.5M
Free Cash Flow
-$17.6M
Op Cash Flow
-$15.3M
EPS Basic
$-2.06
EPS Diluted
$-2.30
EPS Forward
$-1.15
Gross Margin
59.5%
Op Margin
-115.5%
Net Margin
-128.4%
Balance Sheet
Total Assets
$25.2M
Total Liab.
$26.7M
Total Equity
-$1.6M
Cash
$2.0M
LT Debt
$469K
Book Value/Sh
$-0.15
Debt/Equity
-9.06x
Current Ratio
0.24
Quick Ratio
0.24
Returns & Growth
ROE
1420.8%
ROA
-84.2%
ROIC
-123.1%
Rev Growth YoY
+16.1%
EPS Growth YoY
+7.2%
Price Returns
2W
-11.3%
1M
-29.5%
3M
-65.4%
6M
-82.1%
12M
-89.8%
Technicals
52W High
$7.95
52W Low
$0.38
50d MA
$0.65
200d MA
$1.71
RSI (14)
34.10
ATR (14)
$0.07
Beta
6.90
Avg Volume
3.2M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$2.13
High
$2.50
Low
$1.75
Median
$2.12
Data updated apr 27, 2026 8:31am
· Source: financialmodelingprep.com